Brand Name(s):Tivicay
Indication:HIV in combination with other anti-retroviral medicinal products infected adults, adolescents and children above 6 years of age
Rationale:1,2
Considered:Feb-14
Review Date:Jul-23
Comments:
Drug Safety Update
Dolutegravir (Tivicay, Triumeq, Juluca): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception
June 2018 ………………………… Update 2020 – Dolutegravir must now not be administered concurrently with medicinal products with narrow therapeutic windows that are substrates of organic cation transporter 2, including but not limited to fampridine